| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
University of Tennessee Urologic Research Laboratories, Memphis, Tennessee 38163
The chemopreventive efficacy of toremifene, an antiestrogen, was evaluated in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. TRAMP mice were segregated into three groups: (a) the low-dose toremifene group (6.6 mg/kg/day); (b) the high-dose toremifene group (33 mg/kg/day); and (c) the control placebo group. Efficacy of treatment was measured by the absence of palpable tumor. To extend these studies using more sensitive techniques, TRAMP mice were then treated with placebo, flutamide (an antiandrogen; 33 mg/kg/day), or toremifene (10 mg/kg/day). Animals from each treatment group were sacrificed at 7, 10, 15, 20, 25, and 30 weeks of age, and prostate tissues and seminal vesicles were harvested. Tissues from animals (n = 5) in each group were evaluated by wholemount dissections of genitourinary tracts, histology, immunohistochemistry, and Western blot analyses. Blood was pooled per group to measure estradiol and testosterone hormonal levels. Tumors formed at week 17 in the placebo group (n = 10), at week 21 in the high-dose toremifene group (n = 12), and at week 29 in the low-dose toremifene group (n = 12). This represents an increased tumor latency of up to 12 weeks. By 33 weeks, all animals in the placebo group had tumors compared with only 35% of the animals treated with toremifene. Although both flutamide and toremifene decreased tumor incidence compared with the placebo, toremifene was more effective than flutamide. High-grade prostatic intraepithelial neoplasia was observed in animals in the placebo group, but not in animals treated with toremifene. Moreover, toremifene-treated animals had prolonged survival compared with placebo-treated animals. By 33 weeks of age, 100% of the placebo-treated animals had developed palpable tumors and died, whereas 60% of the toremifene-treated animals were tumor free. T antigen levels in the prostate of toremifene-treated animals were similar to those of placebo-treated, age-matched animals. Whereas serum estradiol levels remained unchanged, the total and free testosterone levels were elevated in the toremifene-treated group. Toremifene treatment did not affect androgen receptor levels. Because toremifene prevented prostate cancer in a milieu of elevated blood free testosterone levels with no change in prostate androgen receptor expression, the mechanism of toremifene’s chemopreventive activity may be through nonandrogenic pathways, such as estrogen receptor signaling.
This article has been cited by other articles:
|
|
 |
|
  J. Jayachandran and S. J. Freedland Prevention of Prostate Cancer: What We Know and Where We Are Going American Journal of Men's Health, June 1, 2008; 2(2): 178 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Sargeant, R. D. Klein, R. C. Rengel, S. K. Clinton, S. K. Kulp, Y. Kashida, M. Yamaguchi, X. Wang, and C.-S. Chen Chemopreventive and Bioenergetic Signaling Effects of PDK1/Akt Pathway Inhibition in a Transgenic Mouse Model of Prostate Cancer Toxicol Pathol, June 1, 2007; 35(4): 549 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yin, J. Ni, M. Chen, M. A. DiMaggio, Y. Guo, and S. Yeh The Therapeutic and Preventive Effect of RRR-{alpha}-Vitamin E Succinate on Prostate Cancer via Induction of Insulin-Like Growth Factor Binding Protein-3 Clin. Cancer Res., April 1, 2007; 13(7): 2271 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Fritz, T.-M. Lin, R. D. Cardiff, and R. E. Peterson The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice Carcinogenesis, February 1, 2007; 28(2): 497 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. CARRUBA Estrogens and Mechanisms of Prostate Cancer Progression Ann. N.Y. Acad. Sci., November 1, 2006; 1089(1): 201 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Banach-Petrosky, X. Ouyang, H. Gao, K. Nader, Y. Ji, N. Suh, R. S. DiPaola, and C. Abate-Shen Vitamin d inhibits the formation of prostatic intraepithelial neoplasia in nkx3.1; pten mutant mice. Clin. Cancer Res., October 1, 2006; 12(19): 5895 - 5901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zeng, M. Yokohira, K. Saoo, H. Takeuchi, Y. Chen, K. Yamakawa, Y. Matsuda, Y. Kakehi, and K. Imaida Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor Carcinogenesis, June 1, 2005; 26(6): 1109 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tani, A. Suttie, G. P. Flake, A. Nyska, and R. R. Maronpot Epithelial-Stromal Tumor of the Seminal Vesicles in the Transgenic Adenocarcinoma Mouse Prostate Model Vet. Pathol., May 1, 2005; 42(3): 306 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Cheung, S. Yu, K. B. Wong, L. W. Chan, F. M. M. Lai, X. Wang, M. Suetsugi, S. Chen, and F. L. Chan Expression and Functional Study of Estrogen Receptor-Related Receptors in Human Prostatic Cells and Tissues J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1830 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Adhami, I. A. Siddiqui, N. Ahmad, S. Gupta, and H. Mukhtar Oral Consumption of Green Tea Polyphenols Inhibits Insulin-Like Growth Factor-I-Induced Signaling in an Autochthonous Mouse Model of Prostate Cancer Cancer Res., December 1, 2004; 64(23): 8715 - 8722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Malstrom, O. Tornavaca, A. Meseguer, A. F. Purchio, and D. B. West The Characterization and Hormonal Regulation of Kidney Androgen-Regulated Protein (Kap)-Luciferase Transgenic Mice Toxicol. Sci., June 1, 2004; 79(2): 266 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gupta, V. M. Adhami, M. Subbarayan, G. T. MacLennan, J. S. Lewin, U. O. Hafeli, P. Fu, and H. Mukhtar Suppression of Prostate Carcinogenesis by Dietary Supplementation of Celecoxib in Transgenic Adenocarcinoma of the Mouse Prostate Model Cancer Res., May 1, 2004; 64(9): 3334 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Neubauer, A. M. McNulty, M. Chedid, K. Chen, R. L. Goode, M. A. Johnson, C. D. Jones, V. Krishnan, R. Lynch, H. E. Osborne, et al. The Selective Estrogen Receptor Modulator Trioxifene (LY133314) Inhibits Metastasis and Extends Survival in the PAIII Rat Prostatic Carcinoma Model Cancer Res., September 15, 2003; 63(18): 6056 - 6062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Lippman and W. K. Hong Cancer Prevention Science and Practice Cancer Res., September 15, 2002; 62(18): 5119 - 5125. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
